A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer

Frontiers in Oncology

Oncology

Katie Joanna Miller¹  Hardev Pandha¹  Mohammad Asim¹  Zoe Maylin¹  Christopher Smith¹  IslaHenry¹  Einthavy Arunachalam¹ 

[1] Department of Clinical & Experimental Medicine, University of Surrey, Guildford, United Kingdom;

关键词: AR-V7;    prostate;    castration;    gene;    cancer;   

DOI  :  10.3389/fonc.2023.1129140

 received in 2022-12-21, accepted in 2023-02-13,  发布年份 2023

来源: Frontiers

【 摘 要 】

Persistent androgen receptor (AR) signalling is the main driver of prostate cancer (PCa). Truncated isoforms of the AR called androgen receptor variants (AR-Vs) lacking the ligand binding domain often emerge during treatment resistance against AR pathway inhibitors such as Enzalutamide. This review discusses how AR-Vs drive a more aggressive form of PCa through the regulation of some of their target genes involved in oncogenic pathways, enabling disease progression. There is a pressing need for the development of a new generation of AR inhibitors which can repress the activity of both the full-length AR and AR-Vs, for which the knowledge of differentially expressed target genes will allow evaluation of inhibition efficacy. This review provides a detailed account of the most common variant, AR-V7, the AR-V7 regulated genes which have been experimentally validated, endeavours to understand their relevance in aggressive AR-V driven PCa and discusses the utility of the downstream protein products as potential drug targets for PCa treatment.

【 授权许可】

Unknown   
Copyright © 2023 Miller, Henry, Maylin, Smith, Arunachalam, Pandha and Asim